Pannu, Sonal
Exline, Matthew C.
Bednash, Joseph S.
Englert, Joshua A.
Diaz, Philip
Bartlett, Amy
Brock, Guy
Wu, Qing
Davis, Ian C. http://orcid.org/0000-0002-5308-4776
Crouser, Elliott D.
Funding for this research was provided by:
Foundation for the National Institutes of Health (1U01AI167784-01)
Article History
Received: 26 March 2024
Accepted: 7 May 2024
First Online: 18 May 2024
Declarations
:
: The SCARLET protocol was reviewed and approved by The OSU Institutional Review Board (protocol number 2022H0451). Written, informed consent to participate will be obtained from all participants or their legally authorized representative if incapacitated and deemed unable to provide consent.
: Not applicable.
: I.C.D. is the sole inventor on a patent (US 10,874,684) covering use of citicoline as an ARDS therapeutic, which is assigned to the OSU Innovation Foundation. As such, there is the potential that both could profit from the trial should it result in out-licensing of the technology. However, Dr. Davis is not involved in patient enrollment or data analysis and the OSU Innovation Foundation has played no role in developing or conducting the trial.